NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis $1.82 +0.09 (+5.20%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Reneo Pharmaceuticals Stock (NASDAQ:RPHM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Reneo Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.68▼$1.9050-Day Range$1.31▼$1.8252-Week Range$0.98▼$9.21Volume437,523 shsAverage Volume307,953 shsMarket Capitalization$60.84 millionP/E RatioN/ADividend YieldN/APrice Target$11.01Consensus RatingReduce Company OverviewReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Read More… Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. Reneo Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreRPHM MarketRank™: Reneo Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 570th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingReneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageReneo Pharmaceuticals has received no research coverage in the past 90 days.Read more about Reneo Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.65) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Reneo Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.65% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.65% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.39 News SentimentReneo Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Reneo Pharmaceuticals this week, compared to 1 article on an average week.Search Interest4 people have searched for RPHM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $355,105.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reneo Pharmaceuticals' insider trading history. Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RPHM Stock News HeadlinesBraden Michael Leonard Acquires 29,600 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) StockSeptember 27, 2024 | insidertrades.comBraden Michael Leonard Purchases 55,300 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) StockSeptember 20, 2024 | insidertrades.comNext opportunity for crypto millionsOctober isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…October 6, 2024 | Crypto 101 Media (Ad)OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 MillionOctober 4 at 4:57 PM | globenewswire.comBaosheng Media Gr (NASDAQ:BAOS) Stock Quotes, Forecast and News SummaryOctober 3 at 10:13 PM | benzinga.comReneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKureOctober 2, 2024 | globenewswire.comReneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Buys 29,600 SharesSeptember 27, 2024 | americanbankingnews.comColor Star Tech (NASDAQ:ADD) Stock Quotes, Forecast and News SummarySeptember 12, 2024 | benzinga.comSee More Headlines RPHM Stock Analysis - Frequently Asked Questions How have RPHM shares performed this year? Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of 2024. Since then, RPHM shares have increased by 13.8% and is now trading at $1.82. View the best growth stocks for 2024 here. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.01. When did Reneo Pharmaceuticals IPO? Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/13/2024Today10/06/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$11.01 High Stock Price Target$35.55 Low Stock Price Target$1.50 Potential Upside/Downside+505.1%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.52% Return on Assets-56.36% Debt Debt-to-Equity RatioN/A Current Ratio57.86 Quick Ratio57.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book0.68Miscellaneous Outstanding Shares33,430,000Free Float27,439,000Market Cap$60.84 million OptionableOptionable Beta0.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RPHM) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reneo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.